Leiden, The Netherlands, April 4, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that the Rabies monoclonal antibody product it is developing has entered a Phase I clinical study in India, four months after launching a similar study in the US. Crucell has developed a human monoclonal antibody product for the post-exposure prophylaxis of rabies, using Crucell's MAbstract® and Crucell's PER.C6® technologies. This second Phase I study is closely linked to the initial Phase I study that is currently being performed in the US. Both studies are conducted under FDA authority, the Indian Phase I study gained approval upon review by the Drug Controller-General of India (DCGI).
